Alpa Laboratories

Alpa Laboratories FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Alpa Laboratories (ALPA.NS) as of Oct 17, 2026 is 35.58 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -16.31 % — a change of -318.11% (higher).

FCF Conversion

35.58 %

YoY

-318.11%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Alpa Laboratories is 2025 35.58 % . FCF Conversion Rate (FCF/EBITDA) of Alpa Laboratories was 2024 -16.31 % . It decreases by -318.11% higher compared to the previous year.

The Alpa Laboratories FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-522.66 INR
Jan 1, 2019
-183.67 INR
Jan 1, 2020
822.45 INR
Jan 1, 2021
-67.74 INR
Jan 1, 2022
54.99 INR
Jan 1, 2023
61.82 INR
Jan 1, 2024
-16.31 INR
Jan 1, 2025
35.58 INR
The Alpa Laboratories FCF Conversion history
YEARFCF ConversionYoY
35.58 %-318.11%
-16.31 %-126.39%
61.82 %+12.41%
54.99 %-181.18%
-67.74 %-108.24%
822.45 %-547.78%
-183.67 %-64.86%
-522.66 %-184.59%
617.86 %-230.32%
-474.13 %-320.84%
214.69 %-288.29%
-114.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alpa Laboratories Stock analysis

What does Alpa Laboratories do? Alpa Laboratories Ltd is a pharmaceutical company headquartered in Indore, India, with 318 employees. It operates in the Health Care sector within the Pharmaceuticals industry. The company went public on August 1, 2007. Its product range includes generic and over-the-counter drugs for human and veterinary use, such as capsules, creams, gels, ointments, ear and eye drops, and tablets. Human products feature Ampicillin Capsule, Amoxycillin Trihydrate Capsule, and Paracetamol Tablet, while veterinary products include Alpamin Bolus and Atropine Inj. B.Vet.C. Alpa Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alpa Laboratories stock

FCF Conversion Rate (FCF/EBITDA) of Alpa Laboratories is 35.58 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Alpa Laboratories changed from -16.31 % to 35.58 %, representing a -318.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Alpa Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Alpa Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Alpa Laboratories

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Alpa Laboratories